Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graves Ophthalmopathy | 2 | 2022 | 14 | 0.970 |
Why?
|
| Exophthalmos | 2 | 2022 | 19 | 0.970 |
Why?
|
| Drug Costs | 2 | 2016 | 91 | 0.960 |
Why?
|
| Eyelid Diseases | 2 | 2022 | 21 | 0.950 |
Why?
|
| Eye Diseases | 3 | 2021 | 76 | 0.870 |
Why?
|
| Health Care Costs | 2 | 2016 | 384 | 0.800 |
Why?
|
| Ophthalmologists | 2 | 2020 | 12 | 0.730 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2016 | 1180 | 0.640 |
Why?
|
| Methotrexate | 2 | 2016 | 228 | 0.630 |
Why?
|
| Hemifacial Spasm | 1 | 2018 | 1 | 0.620 |
Why?
|
| Blepharospasm | 1 | 2018 | 7 | 0.610 |
Why?
|
| Botulinum Toxins | 1 | 2018 | 39 | 0.580 |
Why?
|
| Rheumatologists | 1 | 2016 | 12 | 0.560 |
Why?
|
| Behcet Syndrome | 1 | 2016 | 17 | 0.550 |
Why?
|
| Azathioprine | 1 | 2016 | 50 | 0.550 |
Why?
|
| Insurance, Health | 2 | 2016 | 246 | 0.530 |
Why?
|
| Arthritis, Juvenile | 1 | 2016 | 42 | 0.530 |
Why?
|
| Vision Disorders | 1 | 2016 | 130 | 0.500 |
Why?
|
| Uveitis | 1 | 2016 | 115 | 0.500 |
Why?
|
| Glucocorticoids | 2 | 2016 | 552 | 0.500 |
Why?
|
| Uveitis, Posterior | 1 | 2014 | 12 | 0.490 |
Why?
|
| Uveitis, Intermediate | 1 | 2014 | 7 | 0.480 |
Why?
|
| Ophthalmology | 3 | 2020 | 77 | 0.270 |
Why?
|
| Specialization | 2 | 2016 | 117 | 0.240 |
Why?
|
| Electronic Health Records | 2 | 2020 | 805 | 0.220 |
Why?
|
| Eye Hemorrhage | 1 | 2022 | 1 | 0.210 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2022 | 1 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 666 | 0.200 |
Why?
|
| Blepharitis | 1 | 2022 | 3 | 0.200 |
Why?
|
| Eyelid Neoplasms | 1 | 2022 | 8 | 0.200 |
Why?
|
| Keratitis | 1 | 2022 | 11 | 0.200 |
Why?
|
| Ophthalmoplegia | 1 | 2021 | 8 | 0.190 |
Why?
|
| Cavernous Sinus | 1 | 2021 | 14 | 0.190 |
Why?
|
| Trochlear Nerve Diseases | 1 | 2021 | 6 | 0.190 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2021 | 7 | 0.190 |
Why?
|
| Mucormycosis | 1 | 2021 | 20 | 0.190 |
Why?
|
| Population Health | 1 | 2021 | 45 | 0.190 |
Why?
|
| Orbital Diseases | 1 | 2021 | 25 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 4665 | 0.170 |
Why?
|
| Coinfection | 1 | 2021 | 120 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 136 | 0.170 |
Why?
|
| Decision Making | 2 | 2016 | 791 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 192 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 509 | 0.150 |
Why?
|
| Injections | 1 | 2018 | 161 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 667 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2016 | 137 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2020 | 646 | 0.130 |
Why?
|
| Humans | 14 | 2022 | 115587 | 0.130 |
Why?
|
| Rheumatology | 1 | 2016 | 89 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 761 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2016 | 538 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 273 | 0.110 |
Why?
|
| Health Surveys | 1 | 2014 | 446 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 654 | 0.110 |
Why?
|
| United States | 3 | 2021 | 12295 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2016 | 521 | 0.100 |
Why?
|
| Middle Aged | 3 | 2021 | 26999 | 0.090 |
Why?
|
| Female | 5 | 2021 | 59913 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1829 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2022 | 12608 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2020 | 6264 | 0.080 |
Why?
|
| Adult | 2 | 2021 | 30718 | 0.070 |
Why?
|
| Male | 3 | 2021 | 55949 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 4435 | 0.060 |
Why?
|
| Adolescent | 1 | 2021 | 17889 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 24 | 0.050 |
Why?
|
| Oculomotor Muscles | 1 | 2022 | 40 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 310 | 0.050 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 10 | 0.050 |
Why?
|
| Ketosis | 1 | 2021 | 12 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 146 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2021 | 286 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 153 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 362 | 0.040 |
Why?
|
| Sinusitis | 1 | 2021 | 175 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 169 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 618 | 0.040 |
Why?
|
| Child | 1 | 2016 | 18488 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 585 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1048 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 912 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2800 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2392 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 19251 | 0.010 |
Why?
|